Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Videos>This Video
  Videos

Return

Webinar:
Advance drug discovery by improving dose-response curve set-up

Tecan Group Ltd.

Richard Marcellus, Molecular Biologist, Ontario Institute for Cancer Research Save time and reduce waste while improving data quality for small molecule dose-response curves Titration of small molecules in DMSO is a ubiquitous part of the drug discovery workflow. Traditional methods require serial dilution which can be wasteful in terms of tips, intermediate plates and compounds. This process is also time consuming, and reproducibility from researcher to researcher can be a challenge. Traditionally, laboratories have had to accept the potential for carry-over and accumulated pipetting errors, as well as the high labor costs associated with this task. In addition, many laboratories are not performing scientifically optimal titrations, due to equipment or time restrictions. For example, in vitro drug-drug interaction experiments are often desired, but are too complicated to perform routinely. Low- and medium-throughput laboratories, such as therapeutic or lead optimization departments, cannot always justify the purchase of large automation equipment. Not only can the cost of these systems be prohibitive, they can also impose undesirable limits on assay set-up, and often require specialist knowledge to maintain and program. These laboratories need an affordable solution that meets their demands for flexibility, speed and reliability. Join our webinar as we examine the potential for change in dose-response curve set-up for small molecules in DMSO, leading to time savings and dose and plate layout flexibility for drug discovery biologists. Key Learning Objectives • Explore methods to save time and reduce labor costs when setting up dose-response curves • Save precious compounds and eliminate waste of consumables and reagents • Quickly set up drug-drug interaction experiments, along with other complex plate layouts • Improve data quality in dose-response curves and decrease the number of bioassay wells required Richard C. Marcellus, Ph.D. Biochemist - Ontario Institute for Cancer Research, Toronto, Canada Richard has spent over a decade working in cancer drug discovery and has broad experience ranging from target identification, to assay development and HTS, SPR-based protein-drug interaction analysis, and drug target validation. He currently works in the Medicinal Chemistry Group at the OICR, a translational research institute. Richard runs in vitro assays in support of SAR programs, and has embarked upon a targeted screening program in patient-derived primary cancer cells. In this study drug sensitivity is being combined with RNAi and deep sequencing to identify promising anti-cancer targets.

Request more information
Company product page

Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!